Mensa Guide
Antimicrobial Therapy
無料Offers In-App Purchases
1.6.57for iPhone, iPad and more
Age Rating
Mensa Guide スクリーンショット
About Mensa Guide
Mensa Guide is a comprehensive antimicrobial guide, providing up-to-date information for the best therapeutic decision in infectious diseases. The content is organized to provide quick access to the essential information, while allowing to easily delve deeper by opening inline notes.
• Tap on any word in the text to navigate to another entry, to check abbreviations, to view notes, to open calculators or to refer to a bibliographic citation.
• Search from the main screen to find entries according to relevant criteria, or use the full-text search for more specific cases.
• Filter among more than 800 microorganisms according to their characteristics.
• Calculate serum antibiotic concentration, estimated glomerular filtration rate and more than 50 other relevant parameters or scores.
• Access the most recent and complete information available. Content is constantly under review according to the evolution of resistance rates, the appearance of new pathogens and antimicrobials, epidemiological changes and the publication of reviews or treatment consensus in the most prestigious journals.
Note: use of the Mensa Guide requires an annual subscription of $19.99 or a monthly subscription of $1.99 (price may vary by region), with a 30-day free trial period. A subscription allows the use of the Mensa Guide on macOS, iPhone and iPad platforms.
--
About auto-renewing subscriptions:
– An in-app subscription is one month for $1.99 or one year for $19.99.
– Payment will be charged to your iTunes Account at confirmation of purchase.
– Subscriptions automatically renew unless auto-renew is turned off at least 24-hours before the end of the current period.
– Your account will be charged for renewal within 24-hours prior to the end of the current period for $1.99 or $19.99.
– Subscriptions may be managed by the user and auto-renewal may be turned off by going to the user's Account Settings after purchase.
– Any unused portion of a free trial period, if offered, will be forfeited when the user purchases a subscription to that publication, where applicable.
Terms & Conditions: http://www.garmenmed.com/terms.html
--
Disclaimer:
This app is not intended for the general public but for health care professionals. Although we make every effort to ensure that the data is accurate, we are not responsible for any errors or omissions that the app may contain. The application of the information provided in a particular situation remains the sole responsibility of the health care professional.
--
We would love to hear your suggestions, recommendations or corrections. Contact us at mensaguide@garmenmed.com
• Tap on any word in the text to navigate to another entry, to check abbreviations, to view notes, to open calculators or to refer to a bibliographic citation.
• Search from the main screen to find entries according to relevant criteria, or use the full-text search for more specific cases.
• Filter among more than 800 microorganisms according to their characteristics.
• Calculate serum antibiotic concentration, estimated glomerular filtration rate and more than 50 other relevant parameters or scores.
• Access the most recent and complete information available. Content is constantly under review according to the evolution of resistance rates, the appearance of new pathogens and antimicrobials, epidemiological changes and the publication of reviews or treatment consensus in the most prestigious journals.
Note: use of the Mensa Guide requires an annual subscription of $19.99 or a monthly subscription of $1.99 (price may vary by region), with a 30-day free trial period. A subscription allows the use of the Mensa Guide on macOS, iPhone and iPad platforms.
--
About auto-renewing subscriptions:
– An in-app subscription is one month for $1.99 or one year for $19.99.
– Payment will be charged to your iTunes Account at confirmation of purchase.
– Subscriptions automatically renew unless auto-renew is turned off at least 24-hours before the end of the current period.
– Your account will be charged for renewal within 24-hours prior to the end of the current period for $1.99 or $19.99.
– Subscriptions may be managed by the user and auto-renewal may be turned off by going to the user's Account Settings after purchase.
– Any unused portion of a free trial period, if offered, will be forfeited when the user purchases a subscription to that publication, where applicable.
Terms & Conditions: http://www.garmenmed.com/terms.html
--
Disclaimer:
This app is not intended for the general public but for health care professionals. Although we make every effort to ensure that the data is accurate, we are not responsible for any errors or omissions that the app may contain. The application of the information provided in a particular situation remains the sole responsibility of the health care professional.
--
We would love to hear your suggestions, recommendations or corrections. Contact us at mensaguide@garmenmed.com
Show More
最新バージョン 1.6.57 の更新情報
Last updated on 2024年04月26日
旧バージョン
• Inclusion of biomarkers of antibiotic-induced renal toxicity (in Syndromes).
• Changes in aminoglycosides, amphotericin B deoxycholate, cephalosporins, ciprofloxacin, colistin, cotrimoxazole, durlobactam, ertapenem, fosfomycin, fosmanogepix, ibrexafungerp, maribavir, olorofim, opelconazole, rezafungin, sulfonamides, tetracyclines, trimethoprim, vancomycin. Apiotrichum, Corynebacterium, Fusarium, Mycoplasma genitalium, Pneumocystis jirovecii, Xylaria, CMV, HDV, influenza. Sepsis and septic shock. Mastitis. Fever and hepatic granulomas. Fever of unknown origin in the immunocompetent patient. Infections associated with biological therapies. Recurrent urinary tract infection. VIRSTA score.
• Changes in aminoglycosides, amphotericin B deoxycholate, cephalosporins, ciprofloxacin, colistin, cotrimoxazole, durlobactam, ertapenem, fosfomycin, fosmanogepix, ibrexafungerp, maribavir, olorofim, opelconazole, rezafungin, sulfonamides, tetracyclines, trimethoprim, vancomycin. Apiotrichum, Corynebacterium, Fusarium, Mycoplasma genitalium, Pneumocystis jirovecii, Xylaria, CMV, HDV, influenza. Sepsis and septic shock. Mastitis. Fever and hepatic granulomas. Fever of unknown origin in the immunocompetent patient. Infections associated with biological therapies. Recurrent urinary tract infection. VIRSTA score.
Show More
Version History
1.6.57
2024年04月26日
• Inclusion of biomarkers of antibiotic-induced renal toxicity (in Syndromes).
• Changes in aminoglycosides, amphotericin B deoxycholate, cephalosporins, ciprofloxacin, colistin, cotrimoxazole, durlobactam, ertapenem, fosfomycin, fosmanogepix, ibrexafungerp, maribavir, olorofim, opelconazole, rezafungin, sulfonamides, tetracyclines, trimethoprim, vancomycin. Apiotrichum, Corynebacterium, Fusarium, Mycoplasma genitalium, Pneumocystis jirovecii, Xylaria, CMV, HDV, influenza. Sepsis and septic shock. Mastitis. Fever and hepatic granulomas. Fever of unknown origin in the immunocompetent patient. Infections associated with biological therapies. Recurrent urinary tract infection. VIRSTA score.
• Changes in aminoglycosides, amphotericin B deoxycholate, cephalosporins, ciprofloxacin, colistin, cotrimoxazole, durlobactam, ertapenem, fosfomycin, fosmanogepix, ibrexafungerp, maribavir, olorofim, opelconazole, rezafungin, sulfonamides, tetracyclines, trimethoprim, vancomycin. Apiotrichum, Corynebacterium, Fusarium, Mycoplasma genitalium, Pneumocystis jirovecii, Xylaria, CMV, HDV, influenza. Sepsis and septic shock. Mastitis. Fever and hepatic granulomas. Fever of unknown origin in the immunocompetent patient. Infections associated with biological therapies. Recurrent urinary tract infection. VIRSTA score.
1.6.56
2024年04月17日
• Review of viral gastroenteritis.
• Changes in liposomal amphotericin B, ertapenem, linezolid, posaconazole and ECOFF values (imipenem, meropenem, tetracycline). Aspergillus, Blastomyces, Clostridioides difficile, Listeria, Plasmodium falciparum, S. aureus, T. pallidum, Ebola. Infectious diarrhea, Fournier's gangrene, mastitis. COPD (prevention of exacerbations).
• Changes in liposomal amphotericin B, ertapenem, linezolid, posaconazole and ECOFF values (imipenem, meropenem, tetracycline). Aspergillus, Blastomyces, Clostridioides difficile, Listeria, Plasmodium falciparum, S. aureus, T. pallidum, Ebola. Infectious diarrhea, Fournier's gangrene, mastitis. COPD (prevention of exacerbations).
1.6.55
2024年04月08日
• Review and update on chronic hepatitis B and the diagnosis of implant-associated infections.
• Inclusion of the CR-KP bacteremia risk score.
• Changes in aztreonam, cefepime, colistin, ethambutol, fluconazole, flucytosine, fosmanogepix, imipenem, metronidazole, minocycline, voriconazole, ECOFF values (amoxicillin, dalbavancin, doxycycline, tetracycline). Lomentospora, Scedosporium. Prophylaxis in the asymptomatic carrier of S. aureus.
• Inclusion of the CR-KP bacteremia risk score.
• Changes in aztreonam, cefepime, colistin, ethambutol, fluconazole, flucytosine, fosmanogepix, imipenem, metronidazole, minocycline, voriconazole, ECOFF values (amoxicillin, dalbavancin, doxycycline, tetracycline). Lomentospora, Scedosporium. Prophylaxis in the asymptomatic carrier of S. aureus.
1.6.54
2024年03月26日
• Update on the treatment of HIV infection.
• Review of Clonorchis sinensis and Opisthorchis.
• Changes in dalbavancin, daptomycin, durlobactam, primaquine, rezafungin, teicoplanin. Acinetobacter, Aspergillus, Candida, Enterococcus, Echinostoma, M. tuberculosis, P. vivax, Pneumocystis, Taenia, adenovirus, parvovirus, polyomavirus, herpes group viruses, RSV, influenza, measles, mumps, lymphocytic choriomeningitis and yellow fever viruses. Endocarditis. Surgical infection prophylaxis.
• Review of Clonorchis sinensis and Opisthorchis.
• Changes in dalbavancin, daptomycin, durlobactam, primaquine, rezafungin, teicoplanin. Acinetobacter, Aspergillus, Candida, Enterococcus, Echinostoma, M. tuberculosis, P. vivax, Pneumocystis, Taenia, adenovirus, parvovirus, polyomavirus, herpes group viruses, RSV, influenza, measles, mumps, lymphocytic choriomeningitis and yellow fever viruses. Endocarditis. Surgical infection prophylaxis.
1.6.53
2024年03月18日
• Changes in multiple entries according to IDSA and ASM recommendations for laboratory diagnosis of infectious diseases.
• Minor changes in ECOFF values (tetracycline) and in other entries.
• Minor changes in ECOFF values (tetracycline) and in other entries.
1.6.52
2024年03月05日
• Review and update on vaginitis, leishmaniasis, dengue and dengue vaccine.
• Changes in ceftazidime/avibactam, ceftriaxone, paromomycin, piperacillin/tazobactam, miltefosine.
• Changes in ceftazidime/avibactam, ceftriaxone, paromomycin, piperacillin/tazobactam, miltefosine.
1.6.51
2024年02月27日
• Review of Helicobacter pylori.
• Changes in ceftolozane/tazobactam, echinocandins, pretomanid, teicoplanin and ECOFF values (cefalexin, cefiderocol, doxycycline, erythromycin, gentamicin, penicillin G, tigecycline). Acinetobacter, Aspergillus, C. difficile, M. abscessus, Nocardia, Paenibacillus, Rhodococcus, S. suis, RSV, SARS-CoV-2. Fever in the neutropenic patient, fever in the injecting drug user, sinusitis, infectious diarrhea, diverticulitis. Infections associated with biologic therapies.
• Changes in ceftolozane/tazobactam, echinocandins, pretomanid, teicoplanin and ECOFF values (cefalexin, cefiderocol, doxycycline, erythromycin, gentamicin, penicillin G, tigecycline). Acinetobacter, Aspergillus, C. difficile, M. abscessus, Nocardia, Paenibacillus, Rhodococcus, S. suis, RSV, SARS-CoV-2. Fever in the neutropenic patient, fever in the injecting drug user, sinusitis, infectious diarrhea, diverticulitis. Infections associated with biologic therapies.
1.6.50
2024年02月18日
• Inclusion of toxic shock syndrome (SST) and perichondritis.
• Inclusion of a calculator to estimate GFR with the CKD-EPI formula using creatinine ± cystatin C.
• Updates on the treatment of Cryptococcus infection.
• Changes in amphotericin B deoxycholate, ECOFF values (ampicillin). Anaerobiospirillum, Bacteroides, Clostridium spp, S. aureus, S. pyogenes. Infection by anaerobic microorganisms, necrotizing fasciitis, fever in the neutropenic patient and recurrent urinary tract infection.
• Inclusion of a calculator to estimate GFR with the CKD-EPI formula using creatinine ± cystatin C.
• Updates on the treatment of Cryptococcus infection.
• Changes in amphotericin B deoxycholate, ECOFF values (ampicillin). Anaerobiospirillum, Bacteroides, Clostridium spp, S. aureus, S. pyogenes. Infection by anaerobic microorganisms, necrotizing fasciitis, fever in the neutropenic patient and recurrent urinary tract infection.
1.6.49
2024年02月08日
Changes in monoclonal antibodies, caspofungin, ceftazidime/avibactam, fexinidazole. Aspergillus, Blautia, Klebsiella spp, Lophomonas, Paracoccidioides, Pneumocystis jirovecii, P. aeruginosa, S. aureus, Treponema pallidum, Trichophyton, Powassan virus, Sapovirus. Pneumonia. Exacerbations of COPD. Infection of a joint prosthesis. Infection of a cardiac electrostimulation device. Infectious diarrhea. Infection by anaerobic microorganisms.
1.6.48
2024年02月02日
• Inclusion of Healthcare-associated meningitis and ventriculitis (in Syndromes).
• Changes in amphotericin B deoxycholate, daptomycin, gentamicin, piperacillin/tazobactam, vancomycin. Aspergillus, C. difficile, Leishmania, Mucor, M. avium, S. aureus, S. pyogenes. Endocarditis, acute meningitis, pneumonia. Prevention of surgical infection.
• Changes in amphotericin B deoxycholate, daptomycin, gentamicin, piperacillin/tazobactam, vancomycin. Aspergillus, C. difficile, Leishmania, Mucor, M. avium, S. aureus, S. pyogenes. Endocarditis, acute meningitis, pneumonia. Prevention of surgical infection.
1.6.47
2024年01月25日
• Inclusion of simnotrelvir/ritonavir and ensitrelvir (in Antimicrobials), and prevention of infections in nursing homes (in Prevention).
• Changes in sarecycline, ECOFF values (amoxicillin/clavulanate). Basidiobolus, CMV, Molluscum contagiosum, M. genitalium, Plasmodium spp, SARS-CoV-2, Serratia, S. aureus. Cystitis. Infectious arthritis. Endocarditis. Pneumonia. Septic shock. Sinusitis. Prevention of surgical infection.
• Changes in sarecycline, ECOFF values (amoxicillin/clavulanate). Basidiobolus, CMV, Molluscum contagiosum, M. genitalium, Plasmodium spp, SARS-CoV-2, Serratia, S. aureus. Cystitis. Infectious arthritis. Endocarditis. Pneumonia. Septic shock. Sinusitis. Prevention of surgical infection.
1.6.46
2024年01月18日
• Review and update of Trypanosoma cruzi.
• Update of EUCAST recommended breakpoints (version 14, January 2024).
• Changes in benznidazole, cefiderocol, ceftazidime/avibactam, colistin, nifurtimox. Aspergillus, Cryptococcus, N. gonorrhoeae, P. aeruginosa, S. aureus, Streptococcus gallolyticus, Strongyloides. Uveitis. Endocarditis. Infection of an intravenous catheter. Biomarkers of infection.
• Update of EUCAST recommended breakpoints (version 14, January 2024).
• Changes in benznidazole, cefiderocol, ceftazidime/avibactam, colistin, nifurtimox. Aspergillus, Cryptococcus, N. gonorrhoeae, P. aeruginosa, S. aureus, Streptococcus gallolyticus, Strongyloides. Uveitis. Endocarditis. Infection of an intravenous catheter. Biomarkers of infection.
1.6.45
2024年01月10日
• Inclusion of Tebipenem (in Antimicrobials).
• Review of HDV treatment.
• Changes in: gepotidacin, lenacapavir, piperacillin/tazobactam. Burkholderia cepacia, Cryptococcus, Mucor, Mycobacterium chelonae, Salmonella, Treponema pallidum. Endocarditis, recurrent urinary tract infection, infection associated with combat-related injuries or severe trauma (prevention).
• Review of HDV treatment.
• Changes in: gepotidacin, lenacapavir, piperacillin/tazobactam. Burkholderia cepacia, Cryptococcus, Mucor, Mycobacterium chelonae, Salmonella, Treponema pallidum. Endocarditis, recurrent urinary tract infection, infection associated with combat-related injuries or severe trauma (prevention).
1.6.44
2024年01月03日
• Inclusion of "Toxoplasma gondii, prevention in hematologic patients" and review of Toxoplasma.
• Inclusion of Spiroplasma (in Microorganisms).
• Addition of pH and osmolarity values for antibiotic, antifungal and antiparasitic iv formulations.
• Changes in: cefiderocol, letermovir. S. aureus, CMV, Pseudomonas spp, Robinsoniella peoriensis. Prevention of fungal infection (Candida spp, Pneumocystis, Aspergillus), prevention of surgical infection.
• Inclusion of Spiroplasma (in Microorganisms).
• Addition of pH and osmolarity values for antibiotic, antifungal and antiparasitic iv formulations.
• Changes in: cefiderocol, letermovir. S. aureus, CMV, Pseudomonas spp, Robinsoniella peoriensis. Prevention of fungal infection (Candida spp, Pneumocystis, Aspergillus), prevention of surgical infection.
1.6.43
2023年12月24日
• Review and update of malaria. Review of uveitis.
• Changes in: cefiderocol, dalbavancin, vancomycin and ECOFF values (amphotericin B deoxycholate). Candida, Clostridioides difficile, HBV, Klebsiella, Listeria monocytogenes, SARS-CoV-2, Streptococcus pyogenes, Toxoplasma gondii. Conjunctivitis, endophthalmitis, keratitis, impetigo, vaginitis. Recurrent urinary tract infection.
• Changes in: cefiderocol, dalbavancin, vancomycin and ECOFF values (amphotericin B deoxycholate). Candida, Clostridioides difficile, HBV, Klebsiella, Listeria monocytogenes, SARS-CoV-2, Streptococcus pyogenes, Toxoplasma gondii. Conjunctivitis, endophthalmitis, keratitis, impetigo, vaginitis. Recurrent urinary tract infection.
1.6.42
2023年12月15日
• Review and update on endophthalmitis and Rift Valley fever virus.
• Changes in: aminoglycosides, monoclonal Ab, ceftazidime/avibactam, ceftibuten, dalbavancin, linezolid, omadacycline, rifampicin. Candida, C. difficile, P. aeruginosa, JC virus, measles virus, influenza virus, parainfluenza, RSV. Endometritis, vaginitis. Prophylaxis in ocular surgery.
• Changes in: aminoglycosides, monoclonal Ab, ceftazidime/avibactam, ceftibuten, dalbavancin, linezolid, omadacycline, rifampicin. Candida, C. difficile, P. aeruginosa, JC virus, measles virus, influenza virus, parainfluenza, RSV. Endometritis, vaginitis. Prophylaxis in ocular surgery.
1.6.41
2023年12月06日
• Review and update on anthrax, infection of a cardiac electrostimulation device, and fever in the patient with HIV infection.
• Changes in: amikacin, gentamicin, tobramycin. Enterococcus, Listeria, M. avium, Candida, CMV, RSV, influenza, Plasmodium. Pyelonephritis, endocarditis (prophylaxis), pleural effusion, asymptomatic bacteriuria, prevention of surgical infection.
• Changes in: amikacin, gentamicin, tobramycin. Enterococcus, Listeria, M. avium, Candida, CMV, RSV, influenza, Plasmodium. Pyelonephritis, endocarditis (prophylaxis), pleural effusion, asymptomatic bacteriuria, prevention of surgical infection.
1.6.40
2023年11月29日
• Inclusion of gepotidacin (in Antimicrobials).
• Review and update of bacterial vaginosis.
• Changes in: liposomal amphotericin, anidulafungin, caspofungin, ceftriaxone, fluconazole, fosmanogepix, ibrexafungerp, posaconazole. Aspergillus, Candida, Echinococcus granulosus, Fusarium, Gardnerella, Mpox. Peritonitis, endocarditis and biomarkers of infection.
• Review and update of bacterial vaginosis.
• Changes in: liposomal amphotericin, anidulafungin, caspofungin, ceftriaxone, fluconazole, fosmanogepix, ibrexafungerp, posaconazole. Aspergillus, Candida, Echinococcus granulosus, Fusarium, Gardnerella, Mpox. Peritonitis, endocarditis and biomarkers of infection.
1.6.39
2023年11月20日
• Inclusion of Pneumonia associated with mechanical ventilation (in Prevention).
• Review and update of Mucorales and Fusarium.
• Changes in fluconazole, isavuconazole, echinocandins, M. tuberculosis, pneumonia and other entries.
• Review and update of Mucorales and Fusarium.
• Changes in fluconazole, isavuconazole, echinocandins, M. tuberculosis, pneumonia and other entries.
1.6.38
2023年11月13日
• Inclusion of Infections in the patient with liver cirrhosis (in Syndromes).
• Review of spontaneous bacterial peritonitis (prevention).
• Changes in amoxicillin, cefazolin, ceftazidime, cloxacillin, daptomycin, voriconazole. Candida and Cryptococcus (taxonomy), Microascus, Staphylococcus plasmocoagulase-negative, S. lugdunensis. Septic shock, biomarkers of inflammation/infection.
• Review of spontaneous bacterial peritonitis (prevention).
• Changes in amoxicillin, cefazolin, ceftazidime, cloxacillin, daptomycin, voriconazole. Candida and Cryptococcus (taxonomy), Microascus, Staphylococcus plasmocoagulase-negative, S. lugdunensis. Septic shock, biomarkers of inflammation/infection.
1.6.37
2023年10月31日
• Review and update of IDU-associated infections and of infective endocarditis.
• Changes in dalbavancin, doxycycline and minocycline. Brucella, Coxiella, Enterococcus, Legionella, M. abscessus, Mycoplasma, S. aureus and T. whipplei. Sinusitis, odontogenic infection.
• Changes in dalbavancin, doxycycline and minocycline. Brucella, Coxiella, Enterococcus, Legionella, M. abscessus, Mycoplasma, S. aureus and T. whipplei. Sinusitis, odontogenic infection.
1.6.36
2023年10月24日
• Inclusion of zoliflodacin (in Antimicrobials).
• Review of infective endocarditis prophylaxis.
• Changes in ceftazidime/avibactam, imipenem/relebactam, meropenem/vaborbactam, omadacycline. Cryptococcus, Mucor, M. chelonae. Infections of the spine, postoperative fever, pharyngotonsillitis, biomarkers of inflammation/infection, antimicrobial treatment failure, surgical infection prevention.
• Review of infective endocarditis prophylaxis.
• Changes in ceftazidime/avibactam, imipenem/relebactam, meropenem/vaborbactam, omadacycline. Cryptococcus, Mucor, M. chelonae. Infections of the spine, postoperative fever, pharyngotonsillitis, biomarkers of inflammation/infection, antimicrobial treatment failure, surgical infection prevention.
1.6.35
2023年10月17日
• Review and update of Mycobacterium leprae.
• Changes in: cefiderocol, ceftazidime/avibactam, clarithromycin, clofazimine, fluconazole, imipenem/relebactam, levofloxacin, meropenem/varbobactam, moxifloxacin. Candida, Cryptococcus, Fusarium, Treponema pallidum. Osteomyelitis. Infection in the neutropenic patient (prevention). Infections associated with biological therapies. Vancomycin dose adjustment calculator.
• Changes in: cefiderocol, ceftazidime/avibactam, clarithromycin, clofazimine, fluconazole, imipenem/relebactam, levofloxacin, meropenem/varbobactam, moxifloxacin. Candida, Cryptococcus, Fusarium, Treponema pallidum. Osteomyelitis. Infection in the neutropenic patient (prevention). Infections associated with biological therapies. Vancomycin dose adjustment calculator.
1.6.34
2023年10月10日
• Inclusion of a vancomycin dose adjustment calculator.
• Review and update of vascular graft infections and tuberculosis.
• Changes in: dalbavancin, delafloxacin, isoniazid and echinocandins. Corynebacterium, S. aureus, Holtiella, Aerococcus, Candida, HSV and influenza vaccine.
• Review and update of vascular graft infections and tuberculosis.
• Changes in: dalbavancin, delafloxacin, isoniazid and echinocandins. Corynebacterium, S. aureus, Holtiella, Aerococcus, Candida, HSV and influenza vaccine.
1.6.33
2023年10月03日
• Review and update of Clostridioides difficile.
• Changes in: dalbavancin, ceftobiprole, piperacillin, rifampicin, valacyclovir. Pseudomona aeruginosa, EBV, SARS-CoV-2. Pneumonia, sepsis and septic shock, skin and subcutaneous tissue infections.
• Changes in: dalbavancin, ceftobiprole, piperacillin, rifampicin, valacyclovir. Pseudomona aeruginosa, EBV, SARS-CoV-2. Pneumonia, sepsis and septic shock, skin and subcutaneous tissue infections.
Mensa Guide FAQ
ここをクリック！地理的に制限されているアプリのダウンロード方法をご参考ください。
次のリストをチェックして、Mensa Guideの最低システム要件をご確認ください。
iPhone
iOS 12.0以降が必要です。
iPad
iPadOS 12.0以降が必要です。
Mac
macOS 10.15以降が必要です。
iPod touch
iOS 12.0以降が必要です。
Mensa Guideは次の言語がサポートされています。 スペイン語, 英語
Mensa Guide二は内課金があります。課金要素と価格をご覧ください。
Monthly Subscription
¥200
Annual Subscription
¥2,100
